Navigation Links
Vion Reports 2007 Fourth Quarter and Year-End Results
Date:3/17/2008

mpany implemented a one-for-ten reverse split of all outstanding shares of its common stock and a corresponding decrease in the number of shares of authorized common stock. Share and per share amounts contained herein are provided on a post-split basis.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to c
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
2. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
3. Warner Chilcott Reports the Death of Its Director James Andress
4. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
5. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
6. Unigene Restates Policy on Analyst Reports
7. NPS Pharmaceuticals Reports 2007 Financial Results
8. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
9. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... (PRWEB) October 30, 2014 Whitehouse Laboratories ... its ICH Stability Testing and Package Test Capacity. Responding ... centers on a dramatic increase in environmental chamber storage ... stability, storage and aging samples to be securely held ... this major capital expenditure has already taken place with ...
(Date:10/30/2014)... 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... management will present a company overview at the Nomura Biotechnology ... in Boston, MA. A ... "Investors & Media" section of the Company,s website, www.isispharm.com ... within 48 hours and will be archived for a limited ...
(Date:10/30/2014)... of the key challenges in the development of quantum ... , In a paper published today (28 October) in ... show how to make a new type of flexibly ... such as high-precision sensors and specialised superfast computers, often ... the methods for trapping these tiny particles are hugely ...
(Date:10/27/2014)... 2014 The new research report, ... & Medium), Sub-type (Primary & Secondary), and End-User ... Transportation & Power Generation) - Trends and Forecasts ... with analysis and forecasting of the market size. ... with 52 Figures spread through 146 Pages and ...
Breaking Biology Technology:Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... 21, 2011 GeneLink, Inc. (OTCBB: GNLK.OB, ... company, reported financial results for the quarter ended September ... Chairman and CEO stated, "From a business development potential, ... in the history of the Company.  The Company continues ...
... The report " Leukemia Therapeutics ... Assessment & Global Market Forecast (2010 - 2020) ... restraints, and opportunities in North America, & Europe. ... TOC on Leukemia Therapeutics Market (Acute/Chronic Lymphocytic Leukemia & ...
... November 18, 2011 Percentage of revenues ... to medical relief organization building a hospital in Ethiopia ... scientific, technical and medical information products and services, announced ... Aid (ICA) through its "Pillars of Hope" ...
Cached Biology Technology:GeneLink Marketing Efforts Poised to Show Results 2GeneLink Marketing Efforts Poised to Show Results 3MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020 2MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020 3Elsevier Supports International Crisis Aid Through 'Pillars of Hope' Campaign 2Elsevier Supports International Crisis Aid Through 'Pillars of Hope' Campaign 3
(Date:10/30/2014)... This news release is available in German . ... we as individuals prompt our fellow humans to behave ... to social dilemmas in game theory. Previous studies assumed ... large groups. Nonetheless, scientists from the Max Planck Institute ... us can exert an influence on the cooperative behaviour ...
(Date:10/30/2014)... Biological membranes are mainly composed of lipid bilayers. ... ions onto lipid membranes helps clarify functional processes ... a quantitative description of the equilibria between lipid ... Zbigniew Figaszewski from the University of Bialystok, Poland, ... findings, just published in EPJ E . ...
(Date:10/29/2014)... to date, researchers have used DNA sequencing to uncover ... Joseph Buxbaum, Ph.D., Icahn School of Medicine at Mount ... of Harvard and MIT, and their colleagues examined more ... unrelated people. They identified changes in 107 genes that ... spectrum disorder (ASD) – a jump from the nine ...
Breaking Biology News(10 mins):Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4Ion adsorption matter in biology 2
... patients whose lungs are implanted with a pencil ... of lung function and report better quality of ... Frank C. Sciurba, M.D., reported today at CHEST ... of Chest Physicians. Scientific sessions continue through Thursday, ...
... home residents contract pneumonia, it is a blow to their ... Jean Mayer USDA Human Nutrition Research Center on Aging at ... concentration in the blood may help reduce the risk of ... data, it appears that daily zinc intake can help nursing ...
... activity in overweight children improves their thinking and reduces ... 200 overweight, inactive children ages 7-11 also showed that ... bone density. Is exercise a magic wand ... are still overweight but less so, with less fat, ...
Cached Biology News:Endobronchial valve significantly improves emphysema 2Zinc may reduce pneumonia risk in nursing home elderly 2Exercise improves thinking, reduces diabetes risk in overweight children 2Exercise improves thinking, reduces diabetes risk in overweight children 3
... to the third cytoplasmic loop of human ... KLH. The immunizing peptide has 79% homology ... Physical form: Solution in phosphate buffered saline, ... Titertest method: IHC (p). Titertest values: ...
... Hot Start Taq Monoclonal ... before the onset of ... amplification and primer-dimer formation. ... raised, the antibody is ...
... Human Pathogenic Viruses The National ... preserves well characterised, authenticated human ... facility, and NCPV is able ... nucleic acids derived from them, ...
... 5 Fluorescein 6-Fam, Hex, Tet ... Fluorescein Tamra Black Hole Quenchers ... Hex, Tet Tamra, Joe 3 ... Institute, New York Double labelled probes are ...
Biology Products: